Literature DB >> 369806

Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

R N Brogden, R C Heel, T M Speight, G S Avery.   

Abstract

Cefoxitin is a beta-lactam antibiotic derived from cephamycin C, a naturally occurring substance produced by Streptomyces lactamdurans. Its resistance to destruction by beta-lactamases results in a broad spectrum of antibacterial activity which includes anaerobic as well as Gram-positive and Gram-negative aerobic bacteria, including many resistant to cephalothin and other cephalosporins. Given by intravenous or intramuscular injection, cefoxitin is effective against a wide variety of infections caused by Gram-positive or Gram-negative aerobes as well as by anaerobic bacteria. It is generally well tolerated, thrombophlebitis, skin rash and some degree of discomfort after intramuscular injection, being the most commonly reported side effects. Cefoxitin has not been shown to cause adverse effects on renal function.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 369806     DOI: 10.2165/00003495-197917010-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  93 in total

1.  Susceptibility of beta-hemolytic streptococci to 65 antibacterial agents.

Authors:  M Finland; C Garner; C Wilcox; L D Sabath
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria.

Authors:  E C Ernst; S Berger; M Barza; N V Jacobus; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

3.  Intravenous cefoxitin sodium in the treatment of urinary tract infections.

Authors:  C E Cox
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

4.  Cefoxitin sodium in complicated urinary tract infection.

Authors:  P J Little; B A Peddie; S Pearson
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

5.  Comparative activities of selected beta-lactam antibiotics against Haemophilus influenzae.

Authors:  J H Jorgensen; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

6.  Surgical considerations in skin and soft-tissue infections and osteomyelitis treated with cefoxitin sodium.

Authors:  R L Perkins
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

7.  In vitro evaluation of cefoxitin and cefamandole.

Authors:  H G Adams; G A Stilwell; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

8.  Susceptibility of Clostridium perfringens isolated from human infections to twenty antibiotics.

Authors:  J D Schwartzman; L B Reller; W L Wang
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

9.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

10.  Antistaphylococcal activity and beta-lactamase resistance of newer cephalosporins.

Authors:  W E Farrar; P K Gramling
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

View more
  11 in total

Review 1.  Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.

Authors:  Young R Lee; Danni McMahan; Catherine McCall; Gregory K Perry
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

2.  Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery.

Authors:  Arantxazu Isla; Iñaki F Trocóniz; Ignacio López de Tejada; Silvia Vázquez; Andrés Canut; Jesús Muriel López; María Ángeles Solinís; Alicia Rodríguez Gascón
Journal:  Eur J Clin Pharmacol       Date:  2012-01-15       Impact factor: 2.953

3.  Cefoxitin: intravenous pharmacokinetics and intramuscular bioavailability in kwashiorkor.

Authors:  N Buchanan; Y Mithal; M Witcomb
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

4.  Treatment of infections due to nonsporing anaerobes.

Authors:  M S Sprott; H R Ingham
Journal:  Drugs       Date:  1979-08       Impact factor: 9.546

Review 5.  Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-04       Impact factor: 9.546

6.  Antibiotic prophylaxis with high-dose cefoxitin in bariatric surgery: an observational prospective single center study.

Authors:  Thibaut Belveyre; Philippe Guerci; Elise Pape; Nathalie Thilly; Kossar Hosseini; Laurent Brunaud; Nicolas Gambier; Claude Meistelman; Marie-Reine Losser; Julien Birckener; Julien Scala-Bertola; Emmanuel Novy
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

7.  Metronidazole v. cefoxitin in severe appendicitis--a trial to compare a single intraoperative dose of two antibiotics given intravenously.

Authors:  A P Corder; T Bates; J E Prior; M Harrison; P J Donaldson
Journal:  Postgrad Med J       Date:  1983-11       Impact factor: 2.401

8.  Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients.

Authors:  R Van Dalen; T B Vree; I M Baars
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

9.  Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.

Authors:  P H Vlasses; A M Holbrook; J J Schrogie; J D Rogers; R K Ferguson; W B Abrams
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

10.  Cefminox versus Cefoxitin in Hysterectomy Prophylaxis : Clinical Efficacy and Serum and Tissue Concentrations.

Authors:  R Garrido; A Novo; S Quintana; M A Macía; L Carrasco; M J de Dios; J M Romo; M Sánchez; M Vargas; M Maciá; F Lapuente; Y Mieza; P Coronet; M Gimeno; A J Carcas; J Frías; V Caballero Fernández
Journal:  Clin Drug Investig       Date:  1997-06       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.